FARPROST-250 Injection

FARPROST-250 Injection is a Carboprost Tromethamine formulation intended for use in hospital-based obstetric and gynaecological care. Carboprost is a prostaglandin analogue that produces uterine contractions and is used in selected clinical situations where controlled uterine activity is required.

The injectable formulation has an established role in obstetric and gynaecological practice, including selected second-trimester pregnancy termination protocols and the management of postpartum uterine bleeding associated with inadequate uterine contraction, where such use is approved and clinically appropriate. By promoting contraction of the uterine musculature, carboprost can assist in achieving the desired therapeutic response.

FARPROST-250 Injection contains Carboprost Tromethamine I.P. 250 mcg in each 1 mL and is supplied as a pack of 5 ampoules. The product is intended for intramuscular administration by qualified healthcare professionals in an appropriately equipped clinical environment.

Its parenteral presentation makes FARPROST-250 relevant to hospitals, obstetric departments, gynaecology units, emergency obstetric services and institutional pharmaceutical procurement programs. The product can form part of a specialized injectable portfolio for clinical settings where prostaglandin-based uterotonic therapy is required.

Carboprost therapy requires appropriate patient assessment because prostaglandins can produce significant uterine and systemic effects. Particular attention is required in patients with respiratory or cardiovascular conditions, and the medicine should be used according to approved prescribing information and established clinical protocols.

For pharmaceutical distributors and institutional healthcare suppliers, FARPROST-250 provides a focused gynaecological injectable option for hospital and obstetric care requirements. Its therapeutic positioning is centered on controlled uterine contraction and selected obstetric indications rather than routine outpatient pharmaceutical use.